Azacitidine
- PDF / 169,780 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 116 Downloads / 132 Views
1 S
No therapeutic response: case report A 33-year-old woman showed no therapeutic response during treatment with azacitidine for relapsed myelodysplasia. The woman, who had diabetes and unspecified therapy-related myelodysplasia, had undergone allogeneic haematopoietic cell transplantation (HCT). Within six months after the transplantation, the myelodysplasia relapsed, and she started receiving azacitidine [route and dosage not stated]. Concurrently, she was on unspecified immunosuppressant therapy. However, no therapeutic response was noted. Additionally, she did not show significant improvement following donor lymphocyte infusions. Subsequently, she developed an erythematous rash on the backs of forearms, wrists, knees and feet, which was attributed to graftversus-host disease (GVHD) [aetiology not stated]. Due to her disease relapse, the woman was scheduled to receive the natural killer cell therapy in a clinical trial. Two weeks before the clinical trial (during admission pre-screening), it was noted that she had chronic intermittent diarrhoea and a week-long history of a pruritic skin rash, which were not related to her GVHD. Further investigation suggested a viral exanthem, and subsequently, COVID-19 was diagnosed. Therefore, her chemotherapy was postponed. She started two weeks of home isolation. Eventually, her COVID-19 improved with resolution of the rash. She was ready to proceed with the planned procedure. Ahmed N, et al. COVID-19 presenting as a viral exanthem and detected during admission prescreening in a hematopoietic cell transplant recipient. Hematology, Transfusion 803504433 and Cell Therapy 42: 215-217, No. 3, Jul-Sep 2020. Available from: URL: http://doi.org/10.1016/j.htct.2020.06.002
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 3 Oct 2020 No. 1824
Data Loading...
